Arthritis Res Ther. 2009;11(3):115. Epub 2009 Jun 22.

Predicting the future of anti-tumor necrosis factor therapy.

Abstract

Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients, reflecting that there are 'responders' as well as 'nonresponders'. Given the destructive nature of RA, the risk of adverse effects, and considerable costs for therapy, there is a strong need to make predictions on success before the start of therapy. In the current issue of Arthritis Research & Therapy, Hueber and colleagues become the first to present a multi-parameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment. Ultimately, this finding may contribute to a personalized form of medicine, whereby a specific therapy will be applied that is best suited to an individual patient.

Comment on

Arthritis Res Ther. 2009;11(3):R76.

PMID:: 19591638; [PubMed - indexed for MEDLINE]
PMCID: PMC2714140

Free PMC Article

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. [Arthritis Res Ther. 2009]
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, et al. Arthritis Res Ther. 2009; 11(3):R76. Epub 2009 May 21.
Review Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. [Pharmacogenomics. 2005]
Review Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.
Ranganathan P. Pharmacogenomics. 2005 Jul; 6(5):481-90.
Review [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis]. [Z Rheumatol. 2002]
Review [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S, Ruof J. Z Rheumatol. 2002; 61 Suppl 2:II/29-32.
Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. [Isr Med Assoc J. 2008]
Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Isr Med Assoc J. 2008 Apr; 10(4):277-81.
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. [Arthritis Rheum. 2007]
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007 Jan; 56(1):13-20.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC

Recent activity

Clear Turn Off Turn On

Predicting the future of anti-tumor necrosis factor therapy.
Predicting the future of anti-tumor necrosis factor therapy.
Arthritis Res Ther. 2009 ;11(3):115. Epub 2009 Jun 22 .

PubMed
Tre1 GPCR initiates germ cell transepithelial migration by regulating Drosophila...
Tre1 GPCR initiates germ cell transepithelial migration by regulating Drosophila melanogaster E-cadherin.
J Cell Biol. 2008 Oct 6 ;183(1):157-68. Epub 2008 Sep 29 .

PubMed
Both common and specialty mushrooms inhibit adhesion molecule expression and in ...
Both common and specialty mushrooms inhibit adhesion molecule expression and in vitro binding of monocytes to human aortic endothelial cells in a pro-inflammatory environment.
Nutr J. 2010 Jul 16 ;9:29.

PubMed
Multiplexed protein measurement: technologies and applications of protein and an...
Multiplexed protein measurement: technologies and applications of protein and antibody arrays.
Nat Rev Drug Discov. 2006 Apr ;5(4):310-20.

PubMed
Serum resistin levels in critically ill patients are associated with inflammatio...
Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients.
Crit Care. 2009 ;13(3):R95. Epub 2009 Jun 19 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: